Viridian Therapeutics Stock Performance
| VRDN Stock | USD 24.26 0.47 1.98% |
On a scale of 0 to 100, Viridian Therapeutics holds a performance score of 13. The entity has a beta of 1.05, which indicates a somewhat significant risk relative to the market. Viridian Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Viridian Therapeutics is expected to follow. Please check Viridian Therapeutics' downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to make a quick decision on whether Viridian Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Viridian Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Viridian Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.98 | Five Day Return 10.57 | Year To Date Return 8.55 | Ten Year Return (96.74) | All Time Return (98.81) |
Last Split Factor 1:15 | Dividend Date 2020-11-13 | Last Split Date 2020-11-13 |
1 | Acquisition by Lara Meisner of 499 shares of Viridian Therapeutics at 18.51 subject to Rule 16b-3 | 08/02/2024 |
2 | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 08/07/2024 |
3 | Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease | 09/10/2024 |
4 | VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints | 09/11/2024 |
5 | Acquisition by Fairmount Funds Management Llc of 1600000 shares of Viridian Therapeutics at 18.75 subject to Rule 16b-3 | 09/13/2024 |
6 | Viridian Therapeutics Trading Down 4.9 percent - MarketBeat | 09/23/2024 |
7 | Insider Buying COO Thomas Beetham Acquires Shares of Viridian Therapeutics Inc | 10/01/2024 |
8 | Insiders turn bullish on these stocks ahead of U.S. elections | 10/10/2024 |
| Begin Period Cash Flow | 155.6 M |
Viridian |
Viridian Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,498 in Viridian Therapeutics on July 20, 2024 and sell it today you would earn a total of 928.00 from holding Viridian Therapeutics or generate 61.95% return on investment over 90 days. Viridian Therapeutics is currently generating 0.8751% in daily expected returns and assumes 5.1843% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Viridian, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viridian Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viridian Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Viridian Therapeutics, and traders can use it to determine the average amount a Viridian Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1688
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VRDN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.18 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.88 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Viridian Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viridian Therapeutics by adding it to a well-diversified portfolio.
Viridian Therapeutics Fundamentals Growth
Viridian Stock prices reflect investors' perceptions of the future prospects and financial health of Viridian Therapeutics, and Viridian Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viridian Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 1.47 B | ||||
| Shares Outstanding | 76.36 M | ||||
| Price To Book | 5.51 X | ||||
| Price To Sales | 6,559 X | ||||
| Revenue | 314 K | ||||
| Gross Profit | (99.12 M) | ||||
| EBITDA | (235.37 M) | ||||
| Net Income | (237.73 M) | ||||
| Cash And Equivalents | 161.21 M | ||||
| Cash Per Share | 5.66 X | ||||
| Total Debt | 21.05 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.77 X | ||||
| Book Value Per Share | 5.16 X | ||||
| Cash Flow From Operations | (184.17 M) | ||||
| Earnings Per Share | (4.25) X | ||||
| Market Capitalization | 1.89 B | ||||
| Total Asset | 490.42 M | ||||
| Retained Earnings | (725.91 M) | ||||
| Working Capital | 459.84 M | ||||
About Viridian Therapeutics Performance
By examining Viridian Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Viridian Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Viridian Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3.7 K | -3.5 K | |
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.55) | (0.52) | |
| Return On Assets | (0.48) | (0.51) | |
| Return On Equity | (0.54) | (0.51) |
Things to note about Viridian Therapeutics performance evaluation
Checking the ongoing alerts about Viridian Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Viridian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viridian Therapeutics is way too risky over 90 days horizon | |
| Viridian Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 314 K. Net Loss for the year was (237.73 M) with loss before overhead, payroll, taxes, and interest of (99.12 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (184.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Viridian Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finbold.com: Insiders turn bullish on these stocks ahead of U.S. elections |
- Analyzing Viridian Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viridian Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Viridian Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viridian Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viridian Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viridian Therapeutics' stock. These opinions can provide insight into Viridian Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.25) | Revenue Per Share 0.005 | Return On Assets (0.33) | Return On Equity (0.54) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.